All News

Adam Colborn, JD, of AMCP, discusses the complexities of drug pricing and what policymakers must consider in efforts to reduce prices and increase access.

Research found that ibrutinib reduces red blood cell aggregation in patients with chronic lymphocytic leukemia (CLL), while obinutuzumab/venetoclax does not significantly alter blood viscosity.

Older adults had a higher risk of dementia if they had varied levels of lipoprotein cholesterol.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Test your knowledge of the first issue of AJMC's anniversary year!

According to research, PSAT1, PSRC1, COLEC12, HP, and PLLP may play a role in small cell lung cancer metabolism, immune response, and tumor progression, though more research is needed.

Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, potentially expanding treatment access for patients.

Suzetrigine (Journavx) is the first new drug approved to treat acute pain in over 20 years and the first to be classified as a selective NaV1.8 pain signal inhibitor, an alternative to opiates.

Travis Brewer, vice president of payer and public health strategy/relations at Texas Oncology, shared that value-based oncology care can achieve both cost efficiency and high-quality outcomes through integrated multidisciplinary teams, flexible payment models, and targeted treatment approaches.

Adam Colborn, JD, of AMCP, discussed how President Trump's rescission of several Biden-era executive orders may impact Medicaid and Medicare initiatives.

Medicare Advantage enrollees, particularly Hispanic and Asian or Pacific Islander decedents, use less end-of-life home health care than those enrolled in traditional Medicare.

A new predictive model developed by Ochsner Health helps clinicians make real-time decisions for patients who had a stroke undergoing urgent carotid intervention, improving chances of regaining functional independence.

The asymptomatic nature of glaucoma makes it imperative to get consistent screening to catch the condition early.

A panel discussion during the JPMorgan conference earlier this month examined where oncology drug development is headed, driven in part by advances in diagnostic testing.

Atezolizumab (Tecentriq) plus chemotherapy after surgery did not improve survival in high-risk triple-negative breast cancer, according to a global phase 3 trial.

A rapid correction of hyperglycemia could be associated with ophthalmic complications based on several cases.

A genetic causal link between rheumatoid arthritis (RA) and an increased risk of traumatic and osteoporotic fractures underscores the need for targeted prevention strategies.

Lower rates of both progression of macular fibrosis and intravitreal aflibercept injections were found in those who used the resveratrol oral supplement.

The CELESTIAL-301 trial evaluating SynKIR-310, a novel chimeric antigen receptor T-cell therapy, has dosed its first patient with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL).

In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent in treating adolescents who have the myasthenia gravis and how nipocalimab works via FcRn blockade to reduce the circulating autoantibodies that drive myasthenia gravis.

Sen. Bill Cassidy, MD, (R, Louisiana) holds a key vote on Robert F. Kennedy Jr's HHS Secretary confirmation. When Cassidy asked for a strategy on Medicare and Medicaid, Kennedy could not provide one.

Although long-term nursing home stay or death decreased before the COVID-19 pandemic, the trend slowed during the pandemic across all racial and ethnic groups.

Patients with myelodysplastic syndromes (MDS) who undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT) are older and face worse outcomes compared with non-MDS patients, according to posters presented at the 2024 American Society of Hematology meeting.

The design of the Enhancing Oncology Model (EOM) was a perfect fit for Minnesota Oncology.

Extranodal non-Hodgkin lymphoma (NHL) makes up over one-third of NHL cases, yet remains understudied and in need of deeper research considerations.

According to a review of hospital-based cross-sectional studies, almost half the type 2 diabetes population is micronutrient deficient.

The latest semaglutide (Ozempic; Novo Nordisk) approval is set to tackle a major need for patients with both type 2 diabetes (T2D) and chronic kidney disease (CKD), addressing their cardiovascular (CV) and kidney disease risks.

First-line maintenance (1LM) niraparib significantly extends progression-free survival (rwPFS) and time to next treatment (rwTTNT) in patients with epithelial ovarian cancer (EOC), with the greatest benefit observed in those considered homologous recombination-deficient (HRd) and those with BRCA-mutated (BRCAm) tumors.

According to the CDC, frequent consumption of sugary drinks is linked to adverse health outcomes that include obesity, type 2 diabetes, heart disease, nonalcoholic liver disease, and gout.

The pause has raised concerns among health officials and state leaders, as the vague wording leaves billions in Medicaid funding at risk, potentially disrupting coverage for millions of Americans.